Musts and no-go therapies for COPD and heart disease

Delegates have been given a low-down on the therapies that should and should not be used in people with COPD and heart disease. Taking ERS congress delegates through the evidence on the safety and efficacy of therapies in a session called “Musts and No-go’s” Professor Claus Vogelmeier, Head of the Department for Pulmonary Medicine at ...

Already a member?

Login to keep reading.

© 2021 the limbic